Research on the drugs used to treat cancer and how well they work. Covers immunotherapy, chemotherapy-free regimens, biosimilars, targeted drugs, and treatment costs.
Dr. Maurizio D'Incalci receives the first Pezcoller-Prodi Award in recognition of his work on translational cancer research and therapeutic oncology. The award highlights his contributions to the development of novel anticancer drugs, including trabectedin.
A recent study found that adult Americans aged 25 and older have become increasingly obese, with 67.6 million estimated to be obese and 65.2 million considered overweight.
Researchers at Mayo Clinic have identified a new epigenomic block that could help stop the progression of many late-stage cancers. This discovery has the potential to improve diagnosis and treatment of advanced disease across various cancer types.
Researchers are using pet dogs with naturally occurring tumors to test new cancer drugs, which could lead to innovative therapies for both humans and animals. The dogs' physiological similarities to humans and conserved genetics between some dog and human cancers make them an ideal model for studying new treatments.
A new study finds that providing direct assistance, such as counseling and nicotine replacement therapy, significantly improves the likelihood of patients quitting smoking. The research team analyzed data from over 1,600 participants who underwent lung cancer screening, finding that active clinician support increased quit rates by 40%.
The Pew Charitable Trusts and Alexander and Margaret Stewart Trust announced five early-career cancer researchers as Pew-Stewart Scholars. They will receive flexible funding to pursue innovative work aimed at advancing progress toward a cure for cancer.
Researchers at Washington University School of Medicine identified a key player in maintaining brain tumor stem cells' ability to survive and replenish themselves. Disrupting this process using protein CDC20 has been shown to reduce tumor growth by up to 95 percent in mice, offering new hope for treating glioblastoma.
Researchers found that mutations in ARID1a gene sensitize certain tumors to PARP inhibitor drugs, allowing for more effective treatment options. The study highlights the importance of using genomic information to guide cancer therapy and identify precise treatments for individual patients.
Researchers have developed a new drug that stimulates tissue stem cells to repair damaged tissues more quickly, showing promise in treating diseases such as ulcerative colitis and bone marrow transplants. The drug, known as SW033291, increases prostaglandin E2 levels and promotes tissue healing without adverse side effects.
A new study published in the American Journal of Public Health found that messages with images depicting the harsh realities of melanoma are more powerful than text-only warnings in persuading young women to reconsider indoor tanning. Loss-framed messages emphasizing the risks of indoor tanning were more effective in decreasing intenti...
Researchers have designed nanoparticles that specifically target cancer stem cells, which are tough to kill with conventional drugs. The treatment successfully killed CSCs and destroyed tumors in mice tests, with no obvious side effects. This therapy may help overcome the defenses of these hardy cells.
Researchers at Johns Hopkins Medicine discovered a protein-signaling process that accelerates the work of the most frequently mutated gene in adult leukemia. A combination of two drugs targeting this process and the gene itself slowed leukemia cell growth in mice, suggesting potential for improved treatment outcomes.
A phase III clinical trial shows necitumumab significantly improves median overall survival in stage IV squamous non-small cell lung cancer patients. The drug's 'fully human' EGFR antibody approach demonstrates potential as a novel immunotherapy strategy.
A small clinical trial found that men with advanced prostate cancer and the AR-V7 gene variant respond to chemotherapy just as well as those without the variant. The study's findings may lead to improved treatment decision-making for patients with prostate cancer.
Researchers at NYU Langone Health have successfully halted and reversed the growth of certain cancerous white blood cells in T-cell acute lymphoblastic leukemia (T-ALL) by blocking a specific protein receptor called CXCR4.
Researchers use 'Google Maps' for cancer genome analysis, identifying potential drug targets and monitoring treatment response. They provide a comprehensive view of the patient's multiple myeloma genome, showing notable mutations and larger-scale changes over time.
A new theranostic agent, I-124 PEG-AVP0458, has shown promise in targeting both ovarian and prostate cancer cells for imaging and treatment. The drug compound attaches itself to the targeted tumor sites via positron emission tomography (PET) scanners, enabling personalized cancer therapy.
Researchers at the Weizmann Institute have developed a three-pronged approach to prevent lung cancer cells from developing resistance to chemotherapy. The new strategy involves targeting two main growth receptor siblings, HER2 and HER3, in addition to an existing anti-EGFR antibody.
Intravenous nutrition source Intralipid reduces chemotherapy side effects by increasing drug bioavailability and targeting cancer treatment, allowing more drugs to reach tumor sites and reducing toxicity.
Researchers from Mount Sinai Health System will present updates on a lymphoma vaccine clinical trial and new treatment strategies in relapsed multiple myeloma. Preliminary results show patients achieving partial or complete clinical remissions, including those with advanced stage disease.
Researchers at VCU Massey Cancer Center have found a promising combination of an experimental drug and common antibiotic Minocycline to target pancreatic cancer cells. The synergistic effect of the two drugs eliminated Stat3 expression, a key protein regulating tumor growth.
The study found that nivolumab improved median overall survival by 2.4 months and doubled the one-year survival rate compared to chemotherapy. The immunotherapy drug also reduced the risk of dying from lung cancer by 41%.
Researchers have discovered how combining AKT inhibitors with radiotherapy may improve cancer treatment outcomes. The study found that targeting specific genes can enhance the efficacy of radiotherapy across various cancer types.
The ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) provides a rational approach to grading the magnitude of clinical benefit of anti-cancer medicines. The scale will be applied to new drugs approved by the EMA, with high-scoring drugs highlighted in the ESMO Clinical Practice Guidelines.
Pacritinib significantly reduced severe spleen enlargement and debilitating side effects in over 20% and 46% of patients, respectively. The therapy also showed promise in treating thrombocytopenia, a life-threatening condition often associated with myelofibrosis.
A recent Mayo Clinic study found that combining the targeted drug ibrutinib with standard chemotherapy significantly reduces the risk of death or cancer progression in patients with relapsed CLL or SLL. The treatment results in a nearly 80% reduction in mortality, offering new hope for longer disease control and decreased risk of relapse.
A Yale University study found that removing more tissue during a partial mastectomy can spare thousands of breast cancer patients from a second surgery. The study showed that cavity shave margins reduced positive margin rates in half without compromising cosmetic outcomes or increasing complication rates.
A University of Colorado Cancer Center study found significant genetic differences between colorectal cancer tumors in young and old patients. The study identified altered gene signaling pathways, including PPAR and IGF1R, which may be involved in the development of younger CRC tumors.
Women treated for gynecologic cancers experience decreased sexual activity, with younger and premenopausal women at higher risk. Counseling during treatment may help alleviate long-term effects on sexual health.
Jim Allison's pioneering work on T-cell response mechanisms led to the development of ipilimumab, a melanoma treatment that has shown unprecedented results in survival rates. His research continues to open new avenues for cancer treatment through immune checkpoint blockade.
The myChoice HRD test predicts response to DNA-damaging agents in ovarian, breast, and pancreatic cancers. A score of ?42 indicates a loss of DNA repair function and reflects tumor sensitivity to PARP inhibitors and platinum-based therapies.
Researchers identified a genetic biomarker that can predict which cancer patients will respond to immunotherapy drugs like pembrolizumab. Patients with mismatch repair gene defects showed improved responses to the treatment, offering hope for previously failed patients. Larger studies are needed to assess the potential for clinical use.
University Hospitals Case Medical Center researchers will present data from several new studies evaluating a potential novel combination treatment for cancer patients with advanced solid tumors. Additionally, experts will analyze gene mutations in small cell lung cancer, revealing significant clinical correlation to overall survival an...
Researchers at Penn's Abramson Cancer Center have made significant advancements in treating advanced BRCA-related ovarian cancer, with over a third of patients responding to olaparib. Additionally, targeted therapy everolimus shows promise in stabilizing disease for advanced thyroid cancer patients who stop responding to sorafenib, and...
A phase I/II clinical trial found that brigatinib responded to treatment in 58 of 78 ALK+ patients, with a 13.4-month progression-free survival rate for those previously treated with crizotinib. Brigatinib also showed promise in treating brain metastases, with a 30% decrease in tumor size and controlled disease for 15.6 months.
Experts say state regulations targeting indoor tanning could drive national policies to reduce skin cancer cases and associated costs. The US Food and Drug Administration has implemented class II device rules for tanning machines, but critics argue these standards are insufficient.
Researchers at the University of Michigan have identified the genetic blueprint of a bacteria that produces ET-743, a compound extracted from a marine invertebrate. This discovery expands understanding of the microbe and could lead to lab-grown production of the cancer-fighting drug.
A new study found that cancer patients' attitudes and beliefs about complementary and alternative medicine are key predictors of its use. Researchers identified specific factors such as expectation of therapeutic benefits, cost concerns, and physician opinions, which varied by sex, race, and education level.
A genetically engineered herpes virus has been shown to halt the progression of skin cancer by killing cancer cells and sparking an immune system response against tumours. The trial involved 436 patients and showed a durable treatment response in 16.3% of patients, with responses extending past three years.
Researchers at the University of Pittsburgh School of Medicine have identified two new classes of RNAs associated with breast cancer biomarker YB-1, which may play a role in prostate cancer progression. The discovery could lead to the development of new cancer treatments and provide insights into human biology.
A new gene subgroup has been identified as a key driver of prostate cancer, allowing for the development of personalized treatment options. The study found that half of all prostate cancer patients have mutations in either C-MYC or L-MYC genes, which can influence disease aggression and treatment response.
Dana-Farber Cancer Institute scientists have developed a new, potent form of targeted cancer therapy using tumor cells' own protein-chopping machinery. The approach causes cancer cells to die quickly, potentially preventing resistance to conventional targeted therapies.
A large international study found that approximately 90% of cases with advanced prostate cancer harbor clinically actionable genetic anomalies. The researchers sequenced DNA and RNA from tumor biopsy samples to identify potential treatments, shedding light on this aggressive type of cancer.
A comprehensive map of genetic mutations in advanced prostate cancers has been created, revealing that nearly 90% of patients have actionable mutations. This breakthrough could lead to targeted treatments and improve patient outcomes.
A recent study has identified genetic abnormalities in prostate cancer that can be targeted with existing or potential drugs, providing a new approach to treatment. The research found that nearly all tumors had at least one genetic aberration, including mutations in the androgen receptor gene.
The Wistar Institute has secured a $5.6 million grant renewal from the Wellcome Trust to further develop cancer drugs targeting Epstein-Barr virus (EBV). The goal is to create a therapeutic that can treat EBV-related cancers by attacking the virus as it remains dormant in patient cells.
A traditional Chinese medicine herbal mixture called Ren Shen Yangrong Tang (RSYRT) significantly reduced fatigue in cancer patients with moderate to severe symptoms. In a Phase I/II trial, RSYRT was found to be safe and effective in improving Qi deficiency, a key factor contributing to fatigue.
Researchers have designed a nanoparticle-based therapy that effectively treats mice with multiple myeloma, a cancer of immune cells in the bone marrow. The nanoparticles carry a Myc inhibitor, which blocks a protein active in many types of cancer, and increase survival by 23 days compared to control groups.
Researchers at University Hospitals Cleveland Medical Center found a new non-invasive stool DNA testing method comparable to colonoscopy for detecting large polyps in African Americans. The study suggests this technology may improve colon cancer screening rates and decrease mortality.
A study has quantified the different mutational profiles of cancer cells in individual tumors, revealing a high degree of variability within one tumor. The researchers found that certain genes behave differently in cancer cells, with some tumors composed of multiple groups with distinct molecular alterations.
Researchers at Oregon State University have developed pactamycin analogs that can cause rapid cell aging and induce premature senescence in cancer cells, slowing or stopping tumor growth. The findings show promise for a new approach to cancer treatment with reduced toxicity and debilitating side effects.
A study published in Annals of Internal Medicine suggests that women with extremely dense breasts do not necessarily need additional imaging after a normal mammogram. However, those with high-risk dense breasts should discuss supplemental screening strategies with their doctors. The American College of Physicians advises 'smarter' canc...
Researchers at the University of Birmingham have found a combination of a cholesterol-lowering drug and a contraceptive steroid to be effective in treating various cancers. The treatment, known as BaP, blocks an enzyme crucial to cancer cell growth and has shown promising results in early stage clinical trials.
Researchers at Cold Spring Harbor Laboratory have discovered the mechanism of action for BRD4, a protein critical to AML cell survival. Disrupting this pathway may lead to improved therapeutic strategies and new molecular targets for treating various cancers.
Researchers at Sandia National Laboratories and the University of Maryland have developed a new cancer treatment method that withholds an essential nutrient from cancer cells, starving them until they self-destruct. The method involves removing asparagine, a nutrient that cancer cells can't produce on their own.
A large study by Boston University School of Medicine researchers found no evidence of an association between Post Traumatic Stress Disorder (PTSD) and cancer incidence. This contradicts plausible theories suggesting a link between stress and cancer, but is consistent with previous population-based studies.
A drug developed in the late 1950s and abandoned due to toxicity has been revived as a treatment for advanced colorectal cancer. The drug, TAS-102, extended patients' overall survival and delayed disease progression with minimal side effects.
A Dartmouth team developed a novel approach for near infrared optical measurements of resected breast tissue using molecular dyes used for surgical specimen margin orientation. This method allows for intraoperative assessment during breast conserving surgery and avoids follow-up resections.
Researchers developed a unique approach using microscopic gas bubbles to deliver directly to cancer cells a viral gene therapy in combination with an experimental drug. The treatment strategy used a novel 'cancer terminator virus' and demonstrated enhanced prostate cancer cell death while sparing healthy cells in preclinical experiments.
Scientists at CSHL have developed a method to comprehensively identify binding pockets inside cancer cells that can be targeted by drugs. Using CRISPR, they surveyed about 200 potential targets and identified six known targets and 19 new ones in leukemia cells.